Nepafenac

Nonsteroidal Anti-inflammatory Drug — SENSORY ORGANS

Key facts

Nepafenac is an ofp drug in the Nonsteroidal Anti-inflammatory Drug class catalogued in DrugCentral. It was first approved by the FDA in 2005. Its mechanism of action is classified as Cyclooxygenase Inhibitors. DrugCentral lists 4 molecular targets, including Ptgs2|Ptgs1, PTGS2 and PTGS1|PTGS2. Recorded indications include Post-Op Ocular Inflammation and Postoperative Ocular Pain.

• Approval status: ofp (first approved 2005 by the FDA).
• Drug class: Nonsteroidal Anti-inflammatory Drug.
• Mechanism of action: Cyclooxygenase Inhibitors.
• Molecular targets: Ptgs2|Ptgs1, PTGS2, PTGS1|PTGS2 and PTGS1 (4 listed in DrugCentral).
• Indications: Post-Op Ocular Inflammation and Postoperative Ocular Pain.
• ATC code: S01BC10 (Antiinflammatory agents, non-steroids).
• Molecular formula: C15H14N2O2; molecular weight 254.29 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Post-Op Ocular Inflammation
• Postoperative Ocular Pain

Contraindications (12)

• Blood coagulation disorder
• Corneal epithelial degeneration
• Corneal erosion
• Corneal ulcer
• Decreased Corneal Sensitivity
• Diabetes mellitus
• Impaired wound healing
• Keratitis
• Ocular Bleeding
• Perforation of cornea
• Rheumatoid arthritis
• Tear film insufficiency

Mechanism & targets

• Mechanism of action (MoA): Cyclooxygenase Inhibitors
• Established pharmacologic class: Nonsteroidal Anti-inflammatory Drug

Molecular targets (4)

Target	Gene	Action	Activity
Cyclooxygenase	Ptgs2|Ptgs1	unknown	IC50 7.00
Prostaglandin G/H synthase 2	PTGS2	inhibitor	IC50 6.82
Cyclooxygenase	PTGS1|PTGS2	unknown	IC50 6.70
Prostaglandin G/H synthase 1	PTGS1	inhibitor	IC50 6.60

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2005-08-19	FDA	—	ALCON PHARMS LTD

ATC classification

ATC code	Therapeutic hierarchy
S01BC10	SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIINFLAMMATORY AGENTS › Antiinflammatory agents, non-steroids

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Ulcerative keratitis	264.9
Corneal opacity	201.9
Toxic anterior segment syndrome	201.0
Corneal oedema	186.3
Macular oedema	174.3
Visual acuity reduced	159.4
Cataract	158.4
Cystoid macular oedema	154.5
Eye pain	148.4
Intraocular pressure increased	144.7
Corneal epithelium defect	144.2
Corneal disorder	131.8

Chemical structure

• Molecular formula: C₁₅H₁₄N₂O₂
• Molecular weight: 254.29 g/mol
• CAS number: 78281-72-8
• InChIKey: QEFAQIPZVLVERP-UHFFFAOYSA-N
• PubChem CID: 151075

NC(=O)CC1=C(N)C(=CC=C1)C(=O)C1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Nepafenac used for?

DrugCentral lists the following indications for Nepafenac: Post-Op Ocular Inflammation and Postoperative Ocular Pain.

How does Nepafenac work?

Nepafenac is classified as Cyclooxygenase Inhibitors; its molecular targets in DrugCentral include Ptgs2|Ptgs1, PTGS2 (inhibitor), PTGS1|PTGS2 and PTGS1 (inhibitor).

When was Nepafenac first approved?

Nepafenac was first approved by the FDA in 2005.

What drug class does Nepafenac belong to?

Nepafenac is in the Nonsteroidal Anti-inflammatory Drug class.

What is the chemical formula of Nepafenac?

Nepafenac has the molecular formula C15H14N2O2 and a molecular weight of 254.29 g/mol.

Sources

• DrugCentral drug card 1899 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1021 — compound record and bioactivity
• PubChem CID 151075 — chemical identifiers
• DrugBank DB06802 — drug record
• FDA UNII 0J9L7J6V8C — substance identity
• DailyMed: FDA labels for Nepafenac — current prescribing information (label search)
• UniProt P35354 (PTGS2) — target protein
• UniProt P23219 (PTGS1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.